The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

You are here: Home / Archives for Uncategorized

Computational Antibody Discovery: State of the Art

by

Join us on June 22 for this free virtual Symposium – Registration is open!

Recent advances in computational and machine learning sciences have had a substantial impact on the antibody discovery process. Novel protocols that incorporate computational approaches can now be used to generate functional antibody therapeutics with good developability. In silico methods complement existing experimental strategies, and their use has become more mainstream in the biopharmaceutical industry. However, the application of computational de novo design strategies requires a thorough understanding of their capabilities, limitations, and experimental validation, as well as their place in the overall discovery pipeline and value chain.

In this Symposium, leading experts in computational antibody discovery from academia and industry will discuss their scientific strategies and progress to date. The event aims to provide a platform for better understanding of the breakthroughs and future directions in this multidisciplinary field, through talks, a panel session, and your questions and insights.

The Symposium commences at 8am PT/11am ET/4pm BST/5pm CET with speakers Drs. Pietro Sormanni, Yanay Ofran, Victor Greiff, Sandeep Kumar, and Ben Holland. The panel session, moderated by Konrad Krawczyk and including Jiye Shi, Tom Diethe and several speakers, will start at ~2pm ET. The Symposium concludes at 3pm ET following final remarks by Andrew Buchanan.

The full agenda is available here.

Biographical information for the Symposium speakers, panelists and hosts can be found here.

Register here for this free Symposium.

“Antibodies to Watch in 2022” is now online!

by

In this 13th installment of the annual ‘Antibodies to Watch’ article series, we discuss key events in commercial antibody therapeutics development that occurred in 2021 and forecast events that might occur in 2022. Regulatory review of antibody therapeutics that target the SARS-CoV-2 coronavirus proceeded at an unprecedented pace in 2021, resulting in both emergency use authorizations and full approvals for sotrovimab, regdanvimab, REGEN-COV2, as well as others, in numerous countries. As of November 1, a total of 11 antibody therapeutics had been granted first approvals in either the United States or European Union in 2021 (evinacumab, dostarlimab loncastuximab tesirine, amivantamab, aducanumab, tralokinumab, anifrolumab, bimekizumab, tisotumab vedotin, regdanvimab, REGEN-COV2). The first global approvals of seven products, however, were granted elsewhere, including Japan (pabinafusp alfa), China (disitamab vedotin, penpulimab, zimberelimab), Australia (sotrovimab, REGEN-COV2), or the Republic of Korea (regdanvimab).

Globally, at least 27 novel antibody therapeutics are undergoing review by regulatory agencies. First actions by the Food and Drug Administration on the biologics license applications for faricimab, sutimlimab, tebentafusp, relatlimab, sintilimab, ublituximab and tezepelumab are expected in the first quarter of 2022. Finally, our data show that, with antibodies for COVID-19 excluded, the late-stage commercial clinical pipeline of antibody therapeutics grew by over 30% in the past year. Of those in late-stage development, marketing applications for at least 22 may occur by the end of 2022.

The full article can be viewed and downloaded here.

Don’t miss the Supplemental Tables, which include data for 115 antibody therapeutics in late-stage clinical studies!

Season’s Greetings

by

As the end of the year draws nears, we would like to thank our members, sponsors, partners, and many volunteers for their participation and contributions. With this help, we had a very productive year. In particular, we co-organized two Symposia in 2021, and launched our Career Shorts interviews and webinar series on Antibody Discovery & Development, Commercializing Antibody Therapeutics, and Adaptive Immune Receptor Repertoires.

In case you missed either Symposia, recordings from our Emerging Immunotherapeutics for Ovarian Cancer Symposium (co-organized with the Ovarian Cancer Research Alliance) and Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium (co-organized with LAVA Therapeutics) are available On Demand on our YouTube channel.

The Career Shorts interviews are also available on our YouTube channel. In this series, scientists and individuals working within the world of antibodies discuss the experiences that have shaped their careers. In sharing their experiences and advice, we aim to empower the next generation of scientists and leaders working in this field to make confident and informed decisions. Career Shorts is the creation of an exceptionally talented volunteer, Raquel Barroso Ferro.

We hope you will join us in our activities in 2022. In particular, The Adaptive Immune Receptor Repertoire (AIRR) Community of The Antibody Society will hold their 6th meeting during May 16-19, 2022. The “Exploring New Frontiers” meeting will be held in person in La Jolla, CA. The AIRR Community is a research-driven group that is organizing and coordinating stakeholders in the use of next-generation sequencing technologies to study antibody/B-cell and T-cell receptor repertoires.

Our volunteer experts in antibody engineering, Drs. Alicia Chenoweth and Silvia Crescioli, will apply their formidable knowledge of this area to create a searchable table of antibody therapeutics in late-stage clinical studies that will appear online in Q1 2022. Their very useful searchable table of antibody therapeutics that are approved or in review in the European Union or United States is already online.

In addition, we are planning a Symposium on Biopharmaceutical Informatics, tentatively scheduled for September 2022, and we will start a new Graduate Student/Post-doc Research Competition. When available, details for these new programs will be posted on our website and sent via email to members.

Our best wishes to you and yours for a wonderful holiday and a happy new year in 2022!

Did you miss our free Symposium on novel γδ-T cell-directed treatments for cancer?

by

“Emerging cancer therapies leveraging gamma-delta effector T cells”

Hosted by The Antibody Society and co-organized with LAVA Therapeutics.

Empowering the potent and specific anti-tumor activities of γδ-T cells is an emerging and highly exciting approach in the fight against cancer. Two distinct therapeutic approaches are getting particular attention; the first is aimed at tumor-targeted activation using bispecific antibodies or γδ-CART cells, the second involves adoptive transfer or in vivo activation of γδ-T cells. During this symposium you will hear from key opinion leaders about the most recent developments for novel γδ-T cell-directed treatments for cancer, including a panel discussion on key opportunities and perspectives.

Held Monday November 29, 2021, the recorded event is available On Demand!

A panel discussion includes:

· Prof. James Allison, MD Anderson, Houston, TX
· Prof. Padmanee Sharma, MD Anderson, Houston TX
· Prof. Daniel Olive, Imcheck and Aix-Marseille Université, Marseille, FR
· Prof. Jürgen Kuball, University Medical Center, Utrecht, NL
· Dr. Michael Koslowski, GammaDelta Therapeutics, London, UK
· Prof. Hans van der Vliet, LAVA Therapeutics and Amsterdam UMC, Utrecht, NL

Career Shorts Ep 3 – Prof Charlotte Deane

by

Career shorts Ep 3 is now available! Check out this new episode where we talk to Professor Charlotte Deane from the University of Oxford. See below for full details.

Career Shorts Ep 3: https://www.youtube.com/watch?v=4b7P6_F5uHg

 

Our previous episodes can be accessed: https://www.youtube.com/channel/UCg7QsNWgfvkWUPV7gTOLUXA

Career shorts webpage: https://www.antibodysociety.org/career-shorts/

 

About Career Shorts:

In this series, we talk to scientists and individuals working within the world of antibodies about the experiences that have shaped their careers and have got them to where they are today. Our goal by sharing their experiences and advice is to empower the next generation of scientists and leaders working in this field and beyond to make confident and empowered decisions.

 

About Charlotte:

Prof Charlotte Deane ( http://www.stats.ox.ac.uk/~deane/ ) leads the Oxford Protein Informatics group, a research group of over 25 people working on diverse problems across protein structure, immunoinformatics, interaction networks and small molecule drug discovery. She is also Deputy Executive Chair of the Engineering and Physical Sciences and Council and the Covid-19 Response Director for UK Research and Innovation.

Twitter: @OPIGlets

Group website: OPIG (ox.ac.uk)